Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

Fig. 4

Forrest plot of risk of adverse outcomes according to add-on therapy. Hospitalisation for heart failure, composite MACE endpoint of MI, stroke, or cardiovascular (CV) death, and all-cause mortality according to second-line add-on treatment. GLP-1 RA glucagon like peptide-1 receptor agonist, SGLT-2 sodium–glucose cotransporter 2 inhibitor, DPP-4 dipeptidyl peptidase inhibitor. The results visualised in the Forest plot is adjusted for age, comorbidities time in metformin monotherapy, year of inclusion, use of statin, CV risk profile, and sex. DPP-4 inhibitors were used as reference

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840